Trulicity helps lower blood sugar in adults and children ages 10 years and older with type 2 diabetes. It also may reduce major heart risks in adults with type 2 diabetes who have or are at risk for ...

Ozempic (semaglutide) and Trulicity (dulaglutide) are prescription drugs used for people with type 2 diabetes and certain other conditions. Both drugs are injected under the skin. Ozempic and ...

The labeling for Trulicity (dulaglutide; Eli Lilly) has been updated to include use in combination with basal insulin for adults with type 2 diabetes, following approval from the Food and Drug ...

INDIANAPOLIS, June 9, 2019 /PRNewswire/ -- Detailed results from REWIND, the Trulicity ® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major cardiovascular ...

Mounjaro (tirzepatide) and Trulicity (dulaglutide) are prescription medications that help manage blood sugar levels in adults with type 2 diabetes. Though they work in slightly different ways, they ...

ST. PETERSBURG, Fla. — Diabetic patients are dealing with a nationwide shortage of Trulicity. The drug is similar to Ozempic which many people are also using to lose weight. Carol Ann Chapetto said ...

Eli Lilly on Sunday launched a DTC campaign for its injectable diabetes drug Trulicity as it seeks to build market share in the competitive GLP-1 receptor agonist class, which has four other approved ...

- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...

(Reuters) -Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling medication for the disease, in reducing the risk of heart attack and ...

REWIND data showed a consistent effect in people with and without established cardiovascular disease TORONTO, June 10, 2019 /CNW/ - Detailed results from REWIND, the Trulicity ® (dulaglutide) ...